ERBB2 and neoplasm: In the second model, evaluating mice with HER2+ gastric cancer cells, the CAT-179 dosed animals showed a 96% durable tumor regression and significant survival benefit relative to the animals dosed with control NK cells (p < 0.0001) [189].